Enhanced pulmonary accumulation of liposomal amphotericin B (AmBisome) in acute liver transplant failure

被引：16
|
作者：
Heinemann, V [1 ]
Bosse, D [1 ]
Jehn, U [1 ]
Debus, A [1 ]
Wachholz, K [1 ]
Forst, H [1 ]
Wilmanns, W [1 ]
机构：
[1] ZENT KLINIKUM,INST ANAESTHESIOL,AUGSBURG,GERMANY
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1997年 / 40卷 / 02期
关键词：
D O I：
10.1093/jac/40.2.295
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Plasma and tissue concentrations of amphotericin B were determined in a patient treated with liposomal amphotericin B during liver transplant failure. A cumulative rise in amphotericin B plasma concentrations was observed accompanied by an enhanced pulmonary deposition of the drug, Failure of the liver as a major component of the reticuloendothelial system may cause elevated plasma concentrations of liposomal amphotericin B and may consequently enhance deposition of liposomes in the lungs as a substitutive clearing organ.
引用
收藏
页码：295 / 297
页数：3
相关论文
共 50 条
  • [1] A perspective on liposomal amphotericin B (AmBisome®)
    Richardson, M.
    de Pauw, B.
    CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 : 1 - 4
  • [2] AmBisome (Liposomal amphotericin B): A comparative review
    Boswell, GW
    Buell, D
    Bekersky, I
    JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (07): : 583 - 592
  • [3] Liposomal amphotericin B (AmBisome®) in invasive aspergillosis
    Calviño, J
    Lens, XM
    Romero, R
    Galbán, C
    Novoa, D
    Mardaras, J
    Arcocha, V
    Sánchez-Guisande, D
    NEFROLOGIA, 1999, 19 (04): : 294 - 298
  • [4] SAFETY OF LIPOSOMAL AMPHOTERICIN-B (AMBISOME) IN 187 TRANSPLANT RECIPIENTS TREATED WITH CYCLOSPORINE
    RINGDEN, O
    ANDSTROM, E
    REMBERGER, M
    SVAHN, BM
    TOLLEMAR, J
    BONE MARROW TRANSPLANTATION, 1994, 14 : S10 - S14
  • [5] Visceral leishmaniasis in renal transplant recipients: Successful treatment with liposomal amphotericin B (AmBisome)
    Boletis, JN
    Pefanis, A
    Stathakis, C
    Helioti, H
    Kostakis, A
    Giamarellou, H
    CLINICAL INFECTIOUS DISEASES, 1999, 28 (06) : 1308 - 1309
  • [6] Persistent acute tubular toxicity after switch from conventional amphotericin B to liposomal amphotericin B (Ambisome)
    Gerbaud, E
    Tamion, F
    Girault, C
    Clabault, K
    Lepretre, S
    Leroy, J
    Bonmarchand, G
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (02) : 473 - 474
  • [7] The care and feeding of a commercial liposomal product: liposomal amphotericin B (AmBisome®)
    Jensen, Gerard M.
    JOURNAL OF LIPOSOME RESEARCH, 2017, 27 (03) : 173 - 179
  • [8] Ocular penetration of amphotericin B and liposomal amphotericin B (amBisome) in a rabbit model.
    Goldblum, D
    Rohrer, K
    Freuh, BE
    Theurillat, R
    Thormann, W
    Zimmerli, S
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S147 - S147
  • [9] Is liposomal amphotericin B (Ambisome) an effective prophylaxis of mycotic infections after liver transplantation?
    Braun, F
    Rüchel, R
    Lorf, T
    Canelo, R
    Müller, A
    Sattler, B
    Ringe, B
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (04) : 1481 - 1483
  • [10] Liposomal amphotericin B (Ambisome) is safe and effective in the treatment of invasive mycosis in organ transplant patients
    Merhav, H
    Nakache, R
    Houri, I
    Orni-Wasserlauf, R
    TRANSPLANTATION PROCEEDINGS, 2001, 33 (06) : 2937 - 2938
12345